v3.25.2
CONDENSED CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS' EQUITY - USD ($)
$ in Thousands
Common Stock
Additional Paid-in Capital
Adjustment
Additional Paid-in Capital
Accumulated Deficit
Adjustment
Accumulated Deficit
Adjustment
Total
Beginning balance (ASU 2020-06) at Dec. 31, 2023   $ (393)   $ 224   $ (169)  
Beginning balance at Dec. 31, 2023 $ 73   $ 415,045   $ (381,549)   $ 33,569
Beginning balance (in shares) at Dec. 31, 2023 [1] 72,952,124            
Share-based compensation related to stock options     833       833
Share-based compensation related to restricted stock awards     1,146       1,146
Share-based compensation related to restricted stock awards (in shares) [1] 340,550            
Net Income (Loss)         (6,798)   (6,798)
Ending balance at Jun. 30, 2024 $ 73   416,631   (388,123)   28,581
Ending balance (in shares) at Jun. 30, 2024 [1] 73,292,674            
Beginning balance at Mar. 31, 2024 $ 73   415,633   (385,920)   29,786
Beginning balance (in shares) at Mar. 31, 2024 [1] 73,052,124            
Share-based compensation related to stock options     333       333
Share-based compensation related to restricted stock awards     665       665
Share-based compensation related to restricted stock awards (in shares) [1] 240,550            
Net Income (Loss)         (2,203)   (2,203)
Ending balance at Jun. 30, 2024 $ 73   416,631   (388,123)   28,581
Ending balance (in shares) at Jun. 30, 2024 [1] 73,292,674            
Beginning balance at Dec. 31, 2024 $ 76   421,528   (378,393)   43,211
Beginning balance (in shares) at Dec. 31, 2024 [1] 75,850,275            
Ending balance at Mar. 31, 2025 $ 78   427,142   (382,012)   45,208
Ending balance (in shares) at Mar. 31, 2025 [1] 78,133,829            
Beginning balance at Dec. 31, 2024 $ 76   421,528   (378,393)   43,211
Beginning balance (in shares) at Dec. 31, 2024 [1] 75,850,275            
Issuance of common stock under the Sales Agreement, net $ 3   6,809       6,812
Issuance of common stock under the Sales Agreement, net (in shares) [1] 2,775,215            
Share-based compensation related to stock options     599       599
Share-based compensation related to restricted stock awards     368       368
Exercise of warrants and options $ 1   2,367       2,368
Exercise of warrants and options (in shares) [1] 1,106,625            
Net Income (Loss)         (3,455)   (3,455)
Ending balance at Jun. 30, 2025 $ 80   431,671   (381,848)   49,903
Ending balance (in shares) at Jun. 30, 2025 [1] 79,732,115            
Beginning balance at Mar. 31, 2025 $ 78   427,142   (382,012)   45,208
Beginning balance (in shares) at Mar. 31, 2025 [1] 78,133,829            
Issuance of common stock under the Sales Agreement, net $ 2   3,949       3,951
Issuance of common stock under the Sales Agreement, net (in shares) [1] 1,450,036            
Share-based compensation related to stock options     263       263
Share-based compensation related to restricted stock awards     164       164
Exercise of warrants and options     153       153
Exercise of warrants and options (in shares) [1] 148,250            
Net Income (Loss)         164   164
Ending balance at Jun. 30, 2025 $ 80   $ 431,671   $ (381,848)   $ 49,903
Ending balance (in shares) at Jun. 30, 2025 [1] 79,732,115            
[1] Common stock, $0.001 par value; Authorized – as of June 30, 2025 and December 31, 2024 – 185,000,000 shares.